title: Therapeutic periocular vaccination with a subunit vaccine induces higher levels of herpes simplex virus-specific tear secretory immunoglobulin A than systemic vaccination and provides protection against recurrent spontaneous ocular shedding of virus in latently infected rabbits.
abstract: Rabbits latently infected with herpes simplex virus type 1 (HSV-1) were vaccinated either periocularly or systemically with a subunit vaccine (gB2 + gD2) plus adjuvant or adjuvant alone. Tear films were collected daily to measure recurrent infectious HSV-1 shedding. After systemic vaccination, the latently infected rabbits were not protected against recurrent ocular viral shedding (HSV-1-positive tear film cultures/total cultures) compared with either the systemic or periocular adjuvant controls (systemic vaccination = 49 of 972, 5.0%; systemic control = 46 of 972, 4.7%; periocular control = 43 of 930, 4.6%; P > 0.8). In contrast, latently infected rabbits vaccinated periocularly with the same vaccine had significantly reduced recurrent shedding (20 of 1026, 2.0%) compared with controls (P < 0.001) or systemic vaccination (P = 0.0002). Thus, recurrent HSV-1 shedding was significantly reduced by therapeutic local periocular subunit vaccination but not by therapeutic systemic subunit vaccination. Neutralizing antibody titers in the serum of systemically and ocularly vaccinated rabbits was similar. In contrast, HSV-specific tear secretory immunoglobulin A was significantly higher in the ocularly vaccinated group (P < 0.01). These results strongly suggest that in the rabbit, and presumably in humans, the local ocular (mucosal) immune response is much more important than the systemic immune response for therapeutic protection against recurrent ocular HSV-1. Thus development of a therapeutic vaccine against recurrent ocular HSV-1 should be directed at enhancing the local ocular (mucosal) immune response.
authors.affiliation: Cedars-Sinai Medical Center, Burns and Allen Research Institute, Los Angeles, California 90048, USA.
authors.forename: A B
authors.initials: AB
authors.lastname: Nesburn
authors.forename: R L
authors.initials: RL
authors.lastname: Burke
authors.forename: H
authors.initials: H
authors.lastname: Ghiasi
authors.forename: S M
authors.initials: SM
authors.lastname: Slanina
authors.forename: S L
authors.initials: SL
authors.lastname: Wechsler
mesh_terms: D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis; D005123:Eye; D018259:Herpesvirus 1, Human / Q000276:immunology; D022283:Herpesvirus Vaccines; D018928:Immunity, Mucosal; D007070:Immunoglobulin A / Q000096:biosynthesis*; D007322:Instillation, Drug; D016849:Keratitis, Herpetic / Q000276:immunology* / Q000517:prevention & control*; D008297:Male; D009500:Neutralization Tests; D011817:Rabbits; D013666:Tears / Q000821:virology*; D014611:Vaccination; D014759:Viral Envelope Proteins / Q000008:administration & dosage / Q000276:immunology; D014765:Viral Vaccines / Q000008:administration & dosage / Q000276:immunology*; D017735:Virus Latency; D017201:Virus Shedding
chemical_list: D000914:Antibodies, Viral; D022283:Herpesvirus Vaccines; D007070:Immunoglobulin A; D014759:Viral Envelope Proteins; D014765:Viral Vaccines; C069093:herpes simplex virus-1 glycoprotein D vaccine